Participants received single , total doses of IR/ER HB/APAP 22.5 / 975 mg ( intact ; three active tablets ) and 45/1950 mg ( intact and crushed [ encapsulated ] ; six active tablets ) , IR HB/APAP 22.5 / 975 mg ( intact ; three active tablets ) and 45/1950 mg ( intact and crushed [ encapsulated ] ; six active tablets ) , and placebo .